Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Patients with chronic lymphocytic leukemia (CLL) have a suboptimal humoral response to vaccination. Recently, BNT162b2, an mRNA COVID-19 vaccine with a high efficacy of 95% in immunocompetent individuals, was introduced. We investigated the safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Ohad Benjamini, Lior Rokach, Gilad Itchaki, Andrei Braester, Lev Shvidel, Neta Goldschmidt, Shirley Shapira, Najib Dally, Abraham Avigdor, Galia Rahav, Yaniv Lustig, Shirley Shapiro Ben David, Riva Fineman, Alona Paz, Osnat Bairey, Aaron Polliack, Ilana Levy, Tamar Tadmor
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Ferrata Storti Foundation 2021-07-01
סדרה:	Haematologica
גישה מקוונת:	https://haematologica.org/article/view/10351
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!